Background
Methods
Patient Population
Clinical Evaluation
CMR Imaging
CMR Quantitative Analysis of Left Atrial Volume and Emptying Function
CMR Quantitative Analysis of LV Function and Definition of Myocardial Ischemia
ECG Interpretation
Follow-Up
Statistical Analysis
All Patients (n = 210) | LA contractile function ≥ median (n = 96) | LA contractile function < median (n = 114) | P-value | |
---|---|---|---|---|
Clinical Characteristics
| ||||
Age in years | 52 ± 16 | 52 ± 16 | 51 ± 15 | NS |
Female Gender (%) | 87 (41) | 42 (44) | 45 (39) | NS |
Resting Heart Rate | 71 ± 15 | 71 ± 15 | 71 ± 15 | NS |
Hx. of Diabetes (%) | 71 (34) | 32 (33) | 39 (34) | NS |
Hx. of Hypercholesterolemia (%) | 138 (65) | 60 (63) | 78 (68) | NS |
Heavy Tobacco Use (%) | 56 (27) | 24 (25) | 32 (28) | NS |
Hx of PAD (%) | 21 (10) | 6 (6) | 15 (13) | NS |
Hx. of Percutaneous Coronary Intervention (%) | 25 (12) | 12 (13) | 13 (11) | NS |
Hx. of Cardiac Bypass Surgery (%) | 21 (10) | 6 (6) | 15 (13) | NS |
Hx. of Angiographic Coronary Stenosis Before CMR (%) | 45 (21) | 22 (23) | 23 (20) | NS |
Any Hx. of CAD before CMR (%) | 41 (20) | 17 (18) | 24 (21) | NS |
Resting SBP | 145 ± 25 | 148 ± 25 | 142 ± 24 | NS |
Resting DBP | 75 ± 13 | 76 ± 12 | 75 ± 15 | NS |
Medication
| ||||
Beta-blocker (%) | 136 (65) | 55 (57) | 81 (71) | 0.04 |
Calcium Blocker (%) | 52 (25) | 26 (27) | 26 (23) | NS |
Angiotensin-converting enzyme inhibitor (%) | 103 (49) | 51 (53) | 52 (46) | NS |
Aspirin (%) | 116 (55) | 51 (53) | 65 (57) | NS |
Nitrates (%) | 23 (11) | 9 (9) | 14 (12) | NS |
Digoxin (%) | 4 (2) | 1 (1) | 3 (3) | NS |
Rest Electrocardiogram
£
| ||||
Left Atrial Enlargement on ECG (%) | 24 (11) | 13 (14) | 10 (9) | NS |
Left Ventricular Hypertrophy on ECG | 17 (8) | 7 (7) | 10 (9) | NS |
QRS duration (ms) | 100 ± 25 | 97 ± 20 | 102 ± 27 | NS |
Left bundle branch block (%) | 19 (9) | 9 (9) | 10 (9) | NS |
Right bundle branch block (%) | 16 (8) | 3 (3) | 13 (11) | 0.05 |
QTc interval | 439 ± 39 | 433 ± 36 | 443 ± 40 | 0.09 |
Significant Q-waves by Minnesota Code Criteria | 19 (9) | 12 (12) | 7 (6) | NS |
CMR
| ||||
Ao root dimen (mm) | 28 ± 5 | 28 ± 4 | 28 ± 5 | NS |
LVEF (%) | 58 ± 13 | 61 ± 10 | 55 ± 15 | <0.01 |
LV mass (grams) | 142 ± 50 | 139 ± 50 | 145 ± 51 | NS |
LVEDD (mm) | 54 ± 8 | 53 ± 8 | 55 ± 8 | NS |
LVEDV index (ml/m2) | 164 ± 59 | 160 ± 54 | 167 ± 63 | NS |
LVESV index (ml/m2) | 73 ± 50 | 65 ± 41 | 79 ± 57 | 0.04 |
LA Volume index - end-systole (ml/m2) | 51 ± 20 | 45 ± 16 | 57 ± 21 | <0.0001 |
LA Volume index - before atrial contraction (ml/m2) | 41 ± 18 | 72 ± 31 | 88 ± 38 | 0.001 |
LA Volume index - end-diastole (ml/m2) | 30 ± 19 | 21 ± 9 | 39 ± 22 | <0.0001 |
LAEFPassive (%) | 19 ± 12 | 20 ± 12 | 18 ± 12 | NS |
LAEFContractile (%) | 32 ± 15 | 42 ± 7 | 21 ± 13 | <0.0001 |
LAEFTotal (%) | 44 ± 16 | 54 ± 9 | 34 ± 15 | <0.0001 |
Contractile/Passive Ratio | 3.8 ± 19 | 5.1 ± 25 | 2.4 ± 8 | <0.0001 |
Contractile/Total Ratio | 0.57 ± 0.29 | 0.64 ± 0.18 | 0.50 ± 0.37 | <0.0001 |
All MACE (N = 48) | All-Cause Mortality (N = 21) | Non-Fatal Events (N = 27) | |||||||
---|---|---|---|---|---|---|---|---|---|
LRχ2 | HR (95% CI) | P-value | LRχ2 | HR (95% CI) | P-value | LRχ2 | HR | P-value | |
Age (years) | 0.41 | 1.01 (0.99-1.03) | NS | 0.51 | 1.01 (0.98-1.04) | NS | 0.02 | 1.00 (0.97-1.03) | NS |
Female Gender | 2.12 | 1.63 (0.84-3.15) | NS | 4.65 | 2.72 (1.10-6.73) | 0.03 | 0.01 | 1.04 (0.41-2.63) | NS |
Body Mass Index (m/kg2) | 1.62 | 0.96 (0.91-1.02) | NS | 0.19 | 0.98 (0.91-1.06) | NS | 2.19 | 0.94 (0.86-1.02) | NS |
Hx. Percutaneous Coronary Intervention | 3.21 | 2.07 (0.93-4.56) | 0.07 | 0.54 | 1.51 (0.51-4.48) | NS | 1.97 | 2.25 (0.73-6.98) | NS |
Hx. Coronary Bypass Surgery | 3.69 | 2.25 (0.96-5.13) | 0.05 | 0.23 | 1.35 (0.40-4.58) | NS | 3.44 | 2.87 (0.94-8.74) | 0.06 |
Diabetes | 0.49 | 1.27 (0.65-2.47) | NS | 0.01 | 1.00 (0.41-2.42) | NS | 0.07 | 1.14 (0.44-2.96) | NS |
Hypercholesterolemia | 0.10 | 1.12 (0.54-2.34) | NS | 0.82 | 0.67 (0.28-1.61) | NS | 1.53 | 2.19 (0.63-7.59) | NS |
Hx. Heavy Smoking | 0.60 | 1.31 (0.66-2.57) | NS | 0.17 | 0.82 (0.31-2.12) | NS | 1.09 | 1.65 (0.64-4.22) | NS |
Family Hx. CAD | 1.00 | 0.66 (0.29-1.49) | NS | 0.33 | 0.77 (0.32-1.85) | NS | 0.47 | 0.67 (0.21-2.11) | NS |
Medications
| |||||||||
Beta-blocker Use | 4.68 | 2.63 (1.10-6.33) | 0.03 | 4.27 | 4.65 (1.08-19.96) | 0.04 | 1.08 | 1.80 (0.59-5.49) | NS |
Calcium Channel Blocker Use | 1.08 | 1.44 (0.72-2.89) | NS | 0.01 | 0.95 (0.35-2.59) | NS | 1.66 | 1.87 (0.72-4.83) | NS |
ACE Inhibitor Use | 0.05 | 0.93 (0.48-1.79) | NS | 0.01 | 0.98 (0.42-2.31) | NS | 0.74 | 0.66 (0.25-1.70) | NS |
Aspirin Use | 0.97 | 1.42 (0.71-2.83) | NS | 0.04 | 0.92 (0.39-2.18) | NS | 1.43 | 1.88 (0.67-5.27) | NS |
ECG Variables
| |||||||||
History of Atrial Fibrillation on ECG | 2.17 | 2.22 (0.77-6.43) | NS | 1.22 | 2.30 (0.53-10.05) | NS | 0.66 | 1.87 (0.41-8.46) | NS |
Left Atrial Enlargement on ECG | 0.01 | 1.04 (0.36-2.96) | NS | 0.62 | 0.45 (0.06-3.45) | NS | 0.61 | 1.65 (0.47-5.82) | NS |
LVH Voltage and Strain | 1.92 | 1.97 (0.75-5.14) | NS | ** | ** | NS | 7.58 | 4.43 (1.54-12.77) | <0.01 |
Significant Q Waves | 0.64 | 1.53 (0.54-4.39) | NS | 3.73 | 3.00 (0.98-19.12) | 0.05 | ** | ** | ** |
QRS Interval > 120 ms | 0.39 | 0.72 (0.25-2.04) | NS | 0.29 | 0.67 (0.15-2.91) | NS | 0.01 | 1.08 (0.31-3.77) | NS |
Left Bundle Branch Block | 1.21 | 1.71 (0.66-4.44) | NS | 0.05 | 1.18 (0.27-5.15) | NS | 3.31 | 2.84 (0.92-8.74) | 0.07 |
Right Bundle Branch Block | 0.23 | 0.70 (0.17-2.94) | NS | 0.28 | 1.49 (0.34-6.49) | NS | ** | ** | ** |
Significant ST Changes | 1.61 | 1.72 (0.74-3.98) | NS | 0.06 | 0.83 (0.19-3.62) | NS | 3.05 | 2.55 (0.89-7.32) | 0.08 |
Significant T Changes | 0.03 | 1.08 (0.47-2.49) | NS | 0.10 | 1.19 (0.39-3.62) | NS | 0.07 | 0.84 (0.24-2.94) | NS |
Prolonged corrected QT Interval | 5.15 | 2.23 (1.12-4.47) | 0.02 | 1.42 | 1.76 (0.70-4.43) | NS | 4.58 | 2.99 (1.10-8.14) | 0.03 |
CMR Variables of the LV
| |||||||||
LVEDD (mm) | 0.70 | 1.02 (0.98-1.06) | NS | 2.93 | 0.95 (0.90-1.01) | 0.09 | 8.32 | 1.08 (1.02-1.14) | <0.01 |
LVEF (per 10%) | 2.59 | 0.84 (0.68-1.04) | NS | 0.04 | 1.03 (0.75-1.42) | NS | 5.3 | 0.71 (0.54-0.95) | 0.02 |
LVEDVI (per 10 ml/m2) | 0.52 | 1.02 (0.97-1.07) | NS | 4.06 | 0.89 (0.80-1.00) | NS | 6.97 | 1.08 (1.02-1.13) | <0.01 |
LVESVI (per 10 ml/m2) | 3.66 | 1.05 (1.00-1.10) | 0.06 | 1.00 | 0.94 (0.82-1.07) | NS | 10.35 | 1.09 (1.03-1.14) | 0.001 |
LV Mass (gram) | 0.01 | 1.00 (0.99-1.01) | NS | 3.26 | 0.99 (0.98-1.00) | 0.07 | 1.71 | 1.00 (1.00-1.01) | NS |
Segmental Wall Motion Abnormality | 1.18 | 1.49 (0.73-3.06) | NS | 0.66 | 1.49 (0.57-3.93) | NS | 0.17 | 1.24 (0.44-3.49) | NS |
Abnormal LV LGE | 6.33 | 2.47 (1.22-5.00) | NS | 2.12 | 2.08 (0.78-5.59) | NS | 3.91 | 2.69 (1.01-7.18) | 0.05 |
CMR Variables of the LA
| |||||||||
Anteroposterior LA Dimension (mm) | 4.64 | 1.05 (1.00-1.09) | 0.03 | 1.01 | 1.03 (0.97-1.10) | NS | 4.45 | 1.06 (1.00-1.12) | 0.03 |
LAVmax (ml/m2) | 2.50 | 1.01 (1.00-1.03) | NS | 1.60 | 1.01 (0.99-1.04) | NS | 2.94 | 1.02 (1.00-1.04) | 0.09 |
LAVac (ml/m2) | 3.16 | 1.02 (1.00-1.03) | 0.08 | 2.79 | 1.02 (1.00-1.04) | 0.10 | 2.99 | 1.02 (1.00-1.04) | 0.08 |
LAVmin (ml/m2) | 6.28 | 1.02 (1.00-1.03) | 0.01 | 6.48 | 1.02 (1.00-1.03) | 0.01 | 3.84 | 1.02 (1.00-1.03) | 0.05 |
LAEFPassive(per 10% reduction) | 0.47 | 1.12 (0.81-1.57) | NS | 0.39 | 1.16 (0.73-1.86) | NS | 0.46 | 1.17 (0.74-1.86) | NS |
LAEFContractile(per 10% reduction) |
18.84
|
1.75 (1.36-2.24)
|
<0.0001
|
14.17
|
1.46 (1.20-1.77)
|
<0.001
|
6.94
|
1.35 (1.08-1.70)
|
<0.01
|
LAEFTotal (per 10% reduction) | 10.91 | 1.45 (1.16-1.82) | <0.001 | 10.80 | 1.38 (1.14-1.68) | 0.001 | 5.05 | 1.29 (1.03-1.60) | 0.02 |
Contractile/Passive ratio |
10.64
|
0.94 (0.91-0.98)
|
<0.001
|
1.47
|
0.88 (0.72-1.08)
|
NS
|
11.9
|
0.93 (0.90-0.97)
|
<0.001
|
Contractile/Total Ratio |
10.48
|
0.39 (0.24-0.64)
|
<0.001
|
8.75
|
0.21 (0.08-0.59)
|
<0.01
|
1.21
|
0.48 (0.13-1.77)
|
NS
|